tnb-383b
mAbexperimentalMulti-specific
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 30, 2019 (NCT03933735)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
TNFRSF17 adcc
- T-cell surface glycoprotein CD3 epsilon chainImmunity, passive
CD3E immunity, passive
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03933735 | Phase 1 | Jun 30, 2019 | AbbVie, Teneobio, Inc. |
| NCT04453397 | N/A | — | Teneobio, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Teneobio, Inc. | For profit | 2 | 2 | 2 | 2019 |
| AbbVie | For profit | 1 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1